Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chinyu Su

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Therapeutic Advances in Gastroenterology|August 10, 2023
Presence of risk factors associated with colectomy among patients with ulcerative colitis: a <i>post hoc</i> analysis of data from the tofacitinib OCTAVE ulcerative colitis clinical programDavid T Rubin, Leonardo Salese, Mitchell Cohen, et al.
Journal of Crohn'S & Colitis|March 18, 2019
The Impact of Raising the Bar for Clinical Trials in Ulcerative ColitisBruce E Sands, Adam S Cheifetz, Chudy I Nduaka, et al.
The American Journal of Gastroenterology|October 19, 2002
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitisChinyu Su, Bruce A Salzberg, James D Lewis, et al.
Journal of Crohn'S & Colitis|April 22, 2021
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical TrialsJulian Panés, Séverine Vermeire, Marla C Dubinsky, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 27, 2018
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical TrialsWilliam J Sandborn, Julián Panés, Geert R D'Haens, et al.
Journal of Gastroenterology and Hepatology|November 13, 2023
Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE SustainJessica R Allegretti, Krisztina B Gecse, Michael V Chiorean, et al.
Inflammatory Bowel Diseases|June 1, 2018
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving TofacitinibKevin L Winthrop, Gil Y Melmed, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|September 2, 2020
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient ManagementBruce E Sands, Jean-Frédéric Colombel, Christina Ha, et al.
Journal of Crohn'S & Colitis|December 8, 2020
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING TrialSéverine Vermeire, Chinyu Su, Nervin Lawendy, et al.
Inflammatory Bowel Diseases|July 6, 2022
Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis ProgramEdward V Loftus, Daniel C Baumgart, Krisztina Gecse, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Therapeutic Advances in Gastroenterology|August 10, 2023
Presence of risk factors associated with colectomy among patients with ulcerative colitis: a <i>post hoc</i> analysis of data from the tofacitinib OCTAVE ulcerative colitis clinical programDavid T Rubin, Leonardo Salese, Mitchell Cohen, et al.
Journal of Crohn'S & Colitis|March 18, 2019
The Impact of Raising the Bar for Clinical Trials in Ulcerative ColitisBruce E Sands, Adam S Cheifetz, Chudy I Nduaka, et al.
The American Journal of Gastroenterology|October 19, 2002
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitisChinyu Su, Bruce A Salzberg, James D Lewis, et al.
Journal of Crohn'S & Colitis|April 22, 2021
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical TrialsJulian Panés, Séverine Vermeire, Marla C Dubinsky, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 27, 2018
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical TrialsWilliam J Sandborn, Julián Panés, Geert R D'Haens, et al.
Journal of Gastroenterology and Hepatology|November 13, 2023
Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE SustainJessica R Allegretti, Krisztina B Gecse, Michael V Chiorean, et al.
Inflammatory Bowel Diseases|June 1, 2018
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving TofacitinibKevin L Winthrop, Gil Y Melmed, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|September 2, 2020
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient ManagementBruce E Sands, Jean-Frédéric Colombel, Christina Ha, et al.
Journal of Crohn'S & Colitis|December 8, 2020
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING TrialSéverine Vermeire, Chinyu Su, Nervin Lawendy, et al.
Inflammatory Bowel Diseases|July 6, 2022
Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis ProgramEdward V Loftus, Daniel C Baumgart, Krisztina Gecse, et al.
Pageof 7